Ask AI
ProCE Banner Events

Share

Therapeutic Strategies for HER2-Positive Breast Cancer

A live, interactive webinar to take place post-SABCS, with the advantage of incorporating relevant data updates from the SABCS conference. In addition, there is an online enduring CME/ABIM MOC–Certified on-demand webcast, downloadable slides, and ClinicalThought expert commentary for FAQ’s.

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for medical oncologists and other healthcare professionals who care for patients with breast cancer.

Time and location

Monday, February 27, 2023

7:00 PM - 8:30 PM Eastern Time (ET)

Virtual

Agenda

Welcome and Program Overview  

Treatment of HER2-Positive Early Breast Cancer  

First- and Second-Line Treatment of HER2-Positive Metastatic Breast Cancer  

Third- and Later-Line Treatment of HER2-Positive Metastatic Breast Cancer, Including Considerations With Brain Metastases

Ongoing Trials in HER2-Positive Breast Cancer  

Final Thoughts and Audience Question and Answer Session

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new and emerging therapies into individualized treatment plans for HER2-positive breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies for HER2-positive early-stage breast cancer, considering available evidence, pathologic response to neoadjuvant therapy, expert recommendations, and an understanding of patient issues, challenges, and preferences
  • Integrate recent advances and available clinical data to optimally select first- and second-line HER2-targeted therapies for HER2-positive advanced breast cancer
  • Plan therapeutic strategies for heavily pre-treated HER2-positive breast cancer, considering detection of brain metastases, available evidence, and expert recommendations
  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive breast cancer
  • Identify patients with HER2-positive breast cancer eligible for enrollment on ongoing clinical studies investigating novel therapies 

Accreditation

Joint Accreditation Statement

       

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 
Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by educational grants from Puma Biotechnology, Inc. and Seagen Inc. 

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.